| Literature DB >> 31805526 |
David S Ettinger1, Douglas E Wood2, Charu Aggarwal3, Dara L Aisner4, Wallace Akerley5, Jessica R Bauman6, Ankit Bharat7, Debora S Bruno8, Joe Y Chang9, Lucian R Chirieac10, Thomas A D'Amico11, Thomas J Dilling12, Michael Dobelbower13, Scott Gettinger14, Ramaswamy Govindan15, Matthew A Gubens16, Mark Hennon17, Leora Horn18, Rudy P Lackner19, Michael Lanuti20, Ticiana A Leal21, Jules Lin22, Billy W Loo23, Renato G Martins2, Gregory A Otterson24, Sandip P Patel25, Karen L Reckamp26, Gregory J Riely27, Steven E Schild28, Theresa A Shapiro1, James Stevenson8, Scott J Swanson10, Kurt W Tauer29, Stephen C Yang1, Kristina Gregory, Miranda Hughes30.
Abstract
The NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC) address all aspects of management for NSCLC. These NCCN Guidelines Insights focus on recent updates in immunotherapy. For the 2020 update, all of the systemic therapy regimens have been categorized using a new preference stratification system; certain regimens are now recommended as "preferred interventions," whereas others are categorized as either "other recommended interventions" or "useful under certain circumstances."Entities:
Year: 2019 PMID： 31805526 DOI： 10.6004/jnccn.2019.0059
Source DB: PubMed Journal: J Natl Compr Canc Netw ISSN： 1540-1405 Impact factor: 11.908